Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Patients will be excluded (1) if they have had a heart attack, stroke, hospitalization for congestive heart failure or unstable angina within 90 days before screening, (2) if they have been taking any weight loss drugs, including over-the-counter medications, within 90 days before screening, (3) if they have had a change in body weight greater than 11 pounds within 90 days, (4) if they have or are planning a surgical treatment for excess weight, (5) if they have Type 1 Diabetes Mellitus, (6) if they have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) and (7) if they have had pancreatitis
Supports cognition and may offer brain protection.*
Sources Review of GLP-1 Medicines for Obesity and Symptoms in Menopause Fat Mass Changes During Menopause: a Metaanalysis The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society Vasomotor Symptoms Across the Menopause Transition: Differences Among Women The Impact of the Menopausal Transition on Body Composition and Abdominal Fat Redistribution Wilding JPH et al
Overexpression of zinc finger DHHC-type containing 1 is associated with poor prognosis and cancer cell growth and metastasis in uterine corpus endometrial carcinoma
US$ 29.07
US$ 27.05
US$ 25.78
US$ 21.00
US$ 29.85
US$ 29.39
